Technology | Contrast Media | December 12, 2017

Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance

Scientists evaluate MR-based technology for differentiating treatment effects

Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance

December 12, 2017 — Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology, developed at Sheba Medical Center in Tel-Hashomer, Israel, with technology provided by Brainlab. The software analyzes magnetic resonance (MR) images to differentiate regions of efficient contrast clearance from regions with contrast accumulation in most cranial tumor patients to provide additional insight into post-treatment tumor characteristics.

“In conventional black and white MR images, it is often difficult to tell regions of high vascular activity apart from areas with damaged vasculature,” commented Yael Mardor, professor and chief scientist at The Advanced Technology Center of Sheba Medical Center. “Elements Contrast Clearance Analysis depicts contrast clearance efficiency of blood vessels in color to help clinicians better interpret the MR images and therefore support ongoing treatment assessment.”

Tissues that are highly vascularized and viable, such as active tumor tissue, are able to efficiently clear contrast agent within an hour of contrast injection. Conversely, regions consisting of damaged blood vessels, for example areas of necrosis, are unable to clear contrast agent as quickly, resulting in contrast accumulation. Based on this phenomenon, the software works by acquiring two MRI scans — one at 5 minutes and another at least one hour after injection of a standard dose of contrast agent — and intelligently subtracting the first series from the second to clearly show the difference between contrast clearance and accumulation.

“Elements Contrast Clearance Analysis has become part of our neuro-oncology team’s standard clinical practice, as it is simple, robust and complements our existing workflows,” commented Liam Welsh, M.D., consultant clinical oncologist at The Royal Marsden NHS Foundation Trust. “We have found every one of the scans analyzed for contrast clearance to be of assistance in our clinical decision-making. In the 30 percent of cases in which a subsequent decision was made to move forward with neurosurgery, we have observed a strong correlation between predicted and histologically observed viable tumor.”

Elements Contrast Clearance Analysis can provide critical insight to a multitude of specialties including radiation oncology, neurosurgery, neuro-oncology and neuroradiology.

Watch the VIDEO "How Serious is MRI Gadolinium Retention in the Brain and Body?"

Read the article "Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software"

For more information:

Related Content

Youth Football Changes Nerve Fibers in Brain

Statistically significant clusters (red-colored) showing group differences (Control vs. Football) in white matter strain along the primary (F1) and secondary (F2) fibers. While body of corpus callosum (BBC) showed relative shrinkage in Football group, the other clusters showed relative stretching of fibers. PCR: Posterior Corona Radiata, PLIC: Posterior Limb of Internal Capsule, SCR: Superior Corona Radiata, SLF: Superior Longitudinal Fasciculus, SCC: Splenium of Corpus Callosum. Image courtesy of Kim et al.

News | Neuro Imaging | December 07, 2018
Magnetic resonance imaging (MRI) scans show repetitive blows to the head result in brain changes among youth football...
Siemens Healthineers Debuts Magnetom Altea 1.5T MRI Scanner
Technology | Magnetic Resonance Imaging (MRI) | December 06, 2018
During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
Vital Showcases Enterprise Imaging Advances at RSNA 2018

Global Illumination from Vital Images

News | Enterprise Imaging | November 28, 2018
Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...